• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对奥克林等人的回复。关于“霍普金斯等人。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176”的评论

Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176".

作者信息

Hopkins Ashley M, Kichenadasse Ganessan, Abuhelwa Ahmad Y, McKinnon Ross A, Rowland Andrew, Sorich Michael J

机构信息

College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia.

Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA 5042, Australia.

出版信息

Cancers (Basel). 2021 Jul 27;13(15):3763. doi: 10.3390/cancers13153763.

DOI:10.3390/cancers13153763
PMID:34359664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8345086/
Abstract

We thank Auclin et al. [...].

摘要

我们感谢奥克林等人。[……]

相似文献

1
Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176".对奥克林等人的回复。关于“霍普金斯等人。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176”的评论
Cancers (Basel). 2021 Jul 27;13(15):3763. doi: 10.3390/cancers13153763.
2
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176.关于霍普金斯等人的评论。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176。
Cancers (Basel). 2021 Jul 20;13(14):3624. doi: 10.3390/cancers13143624.
3
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.肺免疫预后指数在接受一线阿替唑单抗联合治疗的非小细胞肺癌患者中的价值：IMPOWER150试验的亚组分析
Cancers (Basel). 2021 Mar 9;13(5):1176. doi: 10.3390/cancers13051176.
4
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.贝伐珠单抗联合化疗基础上加用一线阿替利珠单抗治疗转移性非鳞状非小细胞肺癌：一项基于美国的成本效益分析。
Cancer. 2019 Oct 15;125(20):3526-3534. doi: 10.1002/cncr.32368. Epub 2019 Jul 9.
5
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.阿替利珠单抗联合贝伐珠单抗、紫杉醇和卡铂用于转移性非鳞状非小细胞肺癌患者的一线治疗，包括 突变患者。
Expert Rev Respir Med. 2020 Feb;14(2):125-136. doi: 10.1080/17476348.2020.1701439. Epub 2019 Dec 12.
6
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
7
Reply to Krupenko et al. Comment on "Lee et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer 2020, , 1382".对克鲁彭科等人的回复。关于“李等人。2020年，ALDH1L1功能丧失与二甲双胍治疗联合降低KRAS驱动的肺癌肿瘤生长，，1382”的评论。
Cancers (Basel). 2021 May 7;13(9):2238. doi: 10.3390/cancers13092238.
8
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗转移性非鳞状非小细胞肺癌的成本效果分析。
Adv Ther. 2020 May;37(5):2116-2126. doi: 10.1007/s12325-020-01292-3. Epub 2020 Mar 19.
9
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.循环免疫细胞比值和肿瘤标志物在阿替利珠单抗治疗晚期非小细胞肺癌患者中的潜在预测价值。
Cancer Biomark. 2018;22(3):467-476. doi: 10.3233/CBM-171089.
10
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.BMI 与免疫检查点抑制剂治疗晚期非小细胞肺癌的总生存期的相关性。
JAMA Oncol. 2020 Apr 1;6(4):512-518. doi: 10.1001/jamaoncol.2019.5241.

本文引用的文献

1
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176.关于霍普金斯等人的评论。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176。
Cancers (Basel). 2021 Jul 20;13(14):3624. doi: 10.3390/cancers13143624.
2
Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer.机器学习用于预测尿路上皮癌中免疫检查点抑制剂的生存结果
Cancers (Basel). 2021 Apr 21;13(9):2001. doi: 10.3390/cancers13092001.
3
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
肺免疫预后指数在接受一线阿替唑单抗联合治疗的非小细胞肺癌患者中的价值：IMPOWER150试验的亚组分析
Cancers (Basel). 2021 Mar 9;13(5):1176. doi: 10.3390/cancers13051176.
4
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.阿特珠单抗治疗尿路上皮癌时质子泵抑制剂的伴随使用与生存。
Clin Cancer Res. 2020 Oct 15;26(20):5487-5493. doi: 10.1158/1078-0432.CCR-20-1876. Epub 2020 Sep 15.
5
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.阿特珠单抗治疗尿路上皮癌时伴随抗生素使用与生存的关系。
Eur Urol. 2020 Oct;78(4):540-543. doi: 10.1016/j.eururo.2020.06.061. Epub 2020 Jul 11.
6
Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.开发和验证免疫检查点抑制剂阿特珠单抗治疗晚期肺癌患者的预后模型。
Clin Cancer Res. 2020 Jul 1;26(13):3280-3286. doi: 10.1158/1078-0432.CCR-19-2968. Epub 2020 Feb 21.
7
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.BMI 与免疫检查点抑制剂治疗晚期非小细胞肺癌的总生存期的相关性。
JAMA Oncol. 2020 Apr 1;6(4):512-518. doi: 10.1001/jamaoncol.2019.5241.
8
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.肺免疫预后指数对转移性非小细胞肺癌患者的预后价值
JAMA Oncol. 2019 Oct 1;5(10):1481-1485. doi: 10.1001/jamaoncol.2019.1747.
9
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.评估肺免疫预后指数在接受阿特珠单抗治疗 NSCLC 患者中的生存和反应预测：临床试验的汇总分析。
J Thorac Oncol. 2019 Aug;14(8):1440-1446. doi: 10.1016/j.jtho.2019.04.006. Epub 2019 Apr 15.
10
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.肺免疫预后指数与晚期非小细胞肺癌患者免疫检查点抑制剂疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.